- |
My Account- |
Polo-like kinases (PLKs) are a family of evolutionarily conserved Serine/Threonine kinases, which are characterized by the presence of an N-terminal protein kinase domain and a C-terminal Polo-box domain (PBD), playing an important role in the regulation of cell cycle progression through G2 and M (mitosis). [show the full text]
| Cat.No. | Product Name | Information | Publication | Customer Review |
|---|---|---|---|---|
| S1109 | BI 2536 | BI 2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM. |
 (14)
|
 (7)
|
| S2235 | BI6727 (Volasertib) | BI6727 (Volasertib) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM. |
|
(2)
|
| S1362 | Rigosertib (ON-01910) | Rigosertib (Estybon, Novonex, ON-01910) is a non-ATP-competitive inhibitor of PLK1 (Polo-like kinase 1) with IC50 of 9 nM. |
(1)
|
(2)
|
| S2193 | GSK461364 | GSK461364 inhibits purified Plk1 with Ki of 2 nM. |
(1)
|
|
| S1485 | HMN-214 | HMN-214 (IVX-214) is a potent inhibitor of Polo-like kinase (Plk)1 with IC50 of 118 nM. |
|
|
| S2898 | MLN0905 | MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM. |
|
|
| S1239 | TAK-960 | TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM. |
|
|
|
